LorcaserinCMOAPI has a full range of raw materials and intermediate production of lorcaserin.also has comprehensive detection equipment,passed GMP and DMF certification through mergers and acquisitions, and has a total quality management system.
Lorcaserin General Description
The lorcaserin works by controlling appetite — specifically by activating brain receptors for serotonin, a neurotransmitter that triggers feelings of satiety and satisfaction.Many antidepressant drugs work by preventing the reuptake of serotonin and keeping brain receptors bathed in the chemical.
Intake of food is controlled by satiety center, located in ventromedial nucleus of hypothalamus and hunger center present in lateral hypothalamus.Various inputs from higher centers and gastrointestinal tracts converge in arcuate nucleus, where two types of neurons controlling food intake is present. Firstly, food intake stimulatory group producing agouti-related protein and neuropeptide Y; and secondly, food intake inhibitory group containing cocaine and amphetamine regulated transcript (CART) and pro-opiomelanocortin (POMC) neurons. POMC contains 5-HT 2C receptors, which when activated releases alpha-melanocyte-stimulating hormone (alfa-MSH).Both inhibitory and stimulatory neurons further projects paraventricular nucleus in the hypothalamus.Paraventricular nucleus contains melanocyte 4 receptors (MC4R) that inhibits appetiteIn therapeutic doses lorcaserin acts as a selective 5-HT 2C agonist on POMC neurons, which in turn causes release of alfa MSH. Further alfa MSH acts on MC4R in paraventricular nucleus in the hypothalamus, leading to decrease in appetite. In supratherapeutic doses, lorcaserin also acts on 5-HT 2B and 5-HT 2A receptors.According to clinical trial data submitted by Arena to the FDA, nearly half of dieters without Type 2 diabetes who used the medication lost at least 5% of their starting weight — or an average of 12 lbs. — over a year, compared with 23% of those taking a placebo. For best results, dieters are advised to use the medication together with a healthy diet and exercise program. The approved labeling for Belviq also recommends that people discontinue the drug if they fail to lose 5% of their body weight after 12 weeks; longer treatment is unlikely to lead to meaningful weight loss.Researchers at Arena say their drug is designed to seek out only the serotonin receptors that affect appetite.
How effective is Lorcaserin ?
Lorcaserin, used in combination with diet and exercise, results in modest weight loss of about 12.9 lb (5.8 kg) compared with 5.6 lb (2.5 kg) with placebo.3 On average, about 47% of patients will lose at least 5% of their body weight (about 11.1 lb [5 kg]) compared with 23% of patients receiving placebo (number needed to treat [NNT] = 4).1–3 About 22% of patients will lose at least 10% of their body weight vs. 9% of patients receiving placebo (NNT = 7). This weight loss is maintained, on average, for two years. Weight loss occurs early, and those who do not lose 5% of their body weight in the first three months are unlikely to achieve 5% loss by 52 weeks. Weight loss also occurs in patients with type 2 diabetes who are not taking insulin, although not to the same extent.4 Stopping lorcaserin after one year results in an average weight gain that is within 2.2 lb (1 kg) of baseline.1–3 There is no research on the effect of lorcaserin on mortality, incidence of diabetes, or other patient-oriented outcomes. Study shows,about half the dieters who took lorcaserin for a year in the study lost at least 5% of their body weight, compared to 20% of dieters who took a placebo pill. About one in five lorcaserin users lost 10% or more of their body weight, compared to one out of 14 placebo users.
Obesity is developing into a pandemic in countries like the USA, the UK and India.1–3 The WHO projects that by 2015, about 700 million adults will be clinically obese.4 Obesity is a major public health problem, beyond the disability directly related to excessive adiposity, and it also increases the risk of several chronic diseases such as hypertension, sleep apnoea, diabetes, coronary artery disease and cancer. Clearly, obesity is a serious threat, imposing a vast economic burden on the healthcare system.
Obesity is the second most common preventable cause of death, second only to tobacco use.6 Evidence suggests that weight reduction substantially lowers the risk of related comorbidities and fosters their therapeutic management.7 ,8 Although bariatric surgery has emerged as the most clinically effective strategy for decreasing body weight for people with morbid obesity (body mass index (BMI) ≥40) or for those who cannot be managed otherwise,9 it is a very invasive procedure with significant risks.10 ,11 At this juncture, behavioural therapy, lifestyle modification and pharmacotherapy remain the mainstays of treatment. The most appealing solution for the public in general would be a “weight loss drug”. There are many kinds of weight loss drug, such as sibutramine,orlistat,cetilistat…etc. Lorcaserin is one of the popular use weight loss drug.
Lorcaserin is a selective 5-HT2C receptor agonist that is thought to decrease food intake through the central POMC system. Lorcaserin benefits:
(1).Lorcaserin is used together with diet and exercise to treat obesity.
(2).Lorcaserin is sometimes used to treat obesity that may be related to diabetes, high cholesterol, or high blood pressure.
(3).Lorcaserin will not treat any underlying health condition (such as heart disease, diabetes, high blood pressure).
The most common side effects of Lorcaserin are:
headache, dizziness, fatigue, nausea, dry mouth, constipation, and hypoglycemia (low blood sugar). Other less common but serious side effects include: heart valve problems, changes in attention or memory, mental problems, depression, painful erections, slow heartbeat, a drop in blood cell count, and an increase in the hormone, prolactin.
The National Institutes of Health provides a full list of side effects that you should evaluate and discuss with your doctor before you take the medication. The drug is also not approved for patients who have experienced reactions to Lorcaserin powder or to any of the product components in the past.
In the early stages of testing, researchers were concerned about cardiac issues in patients taking Lorcaserin powder. But the FDA has since concluded that the drug is unlikely to cause the heart valve problems that were at issue in the early studies. However, Lorcaserin HCL powder powder has not been studied in patients with serious valvular heart disease and the FDA recommends that patients with congestive heart failure be especially cautious when taking the medication.
In addition, according to the to the New England Journal of Medicine there are some concerns that the drug may carry a risk of psychiatric or psychological problems, especially for people who are taking certain medications. According to the FDA, users of Lorcaserin HCL powder may experience including serotonin syndrome, particularly when taken with medicines that increase serotonin levels or activate serotonin receptors. These include medications that are used to treat depression and migraine headaches. Lorcaserin HCL powder powder may also cause disturbances in attention or memory.
Where to buy Lorcaserin in bulk?
If you are interested in lorcaserin raw materials, Please help to contact us,We are lorcaserin raw materials supplier for several years,We supply products with competitive price,good customer service and quality products,We are flexible with the customization of orders to suit your specific need and our quick lead time on orders guarantees that you’ll enjoy with our service.Our company has Lorcaserin and its six intermediates on sale
1. Lorcaserin hydrochloride is compound , which can be obtained （R）Lorcaserin hydrochloride , It can be regarded as the marketed Lorcaserin hydrochloride intermediate,
2. Lorcaserin hydrochloride hemihydrate is a drug substance approved by the US FDA for marketing. trade name is Belviq.
3. （R）Lorcaserin hydrochloride is the resolution product of Lorcaserin hydrochloride.
4. Lorcaserin is the base of Lorcaserin hydrochloride casserin.
5. 8-Chloro-1-Methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is the base of product Lorcaserin hydrochloride.
6. 1-[[2-(4-Chlorophenyl)ethyl]amino]-2-chloropropane hydrochloride is intermediate in the process of Lorcaserin hydrochloride.
1. "Lorcaserin Use During Pregnancy". Drugs.com. 4 November 2019. Retrieved 14 January 2020.
2. "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market". U.S. Food and Drug Administration (FDA). 14 January 2020. Retrieved 1 April 2020.
3. "Belviq (lorcaserin hydrochloride) tablet [Eisai, Inc]". DailyMed. Eisai, Inc. August 2012. Archived from the original on 21 October 2013. Retrieved 21 October 2013.
4. "FDA approves Belviq to treat some overweight or obese adults". U.S. Food and Drug Administration (FDA) (Press release). 27 June 2012. Archived from the original on 1 September 2012. Retrieved 14 January 2020. This article incorporates text from this source, which is in the public domain.
5. "Belviq". Trademarkia. 23 June 2011. Archived from the original on 30 June 2012. Retrieved 27 June 2012.